Shares of Twist Bioscience TWST remained unaffected after the company reported Q3 results.
Quarterly Results
Earnings per share were down 22.39% year over year to ($0.82), which missed the estimate of ($0.75).
Revenue of $35,018,000 higher by 65.12% year over year, which beat the estimate of $32,270,000.
Guidance
The upcoming fiscal year's revenue expected to be between $129,000,000 and $132,000,000.
Details Of The Call
Date: Aug 06, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/d5a3xjnj
Price Action
52-week high: $214.07
52-week low: $53.81
Price action over last quarter: Up 6.32%
Company Profile
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
